MapLight Therapeutics, Inc. (MPLT)
NASDAQ • Healthcare
Last close at September 18, 2026 at 20:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Dec 3
in 73 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
MapLight Therapeutics’ preliminary second fiscal quarter of 2026 results, reported September 18, 2026, featured EPS of -$1.32, which topped the -$1.35 estimate by $0.03, while the company posted a GAAP net loss of about $60.2 million, down from roughly $29.8 million a year ago (net income YoY -101.7%). GAAP operating income was also negative at around $63.5 million, consistent with the company’s clinical-stage profile as it advances central nervous system programs such as ML-007C-MA and ML-004 rather than generating commercial revenue. On the cash side, MapLight recorded negative operating cash flow of roughly $44.9 million. On a year-over-year basis, EPS declined -144.4% from -$0.54 a year ago. Consensus for the next period calls for EPS of -$1.18.
About MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. develops clinical-stage biotechnology therapies for severe central nervous system disorders and trades on NASDAQ under the ticker MPLT. The company develops neuropsychiatric drug candidates from a proprietary platform designed to identify and modulate disease-linked neural circuits, and it operates as a subsidiary of Catalyst4, Inc.
Today's Snapshot
So far today, MPLT is trading slightly higher at 10.96, while its sector was firmer.
Trading Volume
Below 10d avg (579.0K)
216K
vs S&P 500 Today
Underperforming Market
-0.88%
Updated: September 21, 2026 at 17:02 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$11.99 - $19.99Sell
- RSI (14)32.56Neutral
- Stochastic %K (14, 3, 3)10.41Buy
- MACD Level (12, 26)-1.27Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.